Future work should quantify these cytokines in treated tumors and employ syngeneic HCC models to evaluate adaptive resistance mechanisms, such as compensatory PD-L1 upregulation or tumor-associated macrophage (TAM) recruitment. The gene discussed is CD274; the disease is hepatocellular carcinoma.